ARDD 2026 talk: AI-discovered rentosertib and a dual-purpose longevity route
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedIn this ARDD 2026 description, Alex Zhavoronkov (Insilico Medicine) is said to report that the AI-discovered drug rentosertib showed Phase 2 functional and biological-age signals, supporting a route from disease approval to longevity. [1]
The description attributes to Alex Zhavoronkov (Insilico Medicine) the takeaway that the AI-discovered drug rentosertib showed Phase 2 functional and biological-age signals. [1]
According to the description, these signals support a "dual-purpose" route from disease approval to longevity. [1]
The description says ARDD was founded by Alex Zhavoronkov in 2014 and made its North American debut in Boston on October 1–3, 2026. [1]
Zhavoronkov's rentosertib takeaway at ARDD 2026
The description attributes a key takeaway to Alex Zhavoronkov of Insilico Medicine, presenting at the 13th Aging Research and Drug Discovery Meeting. According to this takeaway, the AI-discovered drug rentosertib showed Phase 2 functional and biological-age signals. These signals are said to support a "dual-purpose" route from disease approval to longevity. The description does not report the trial's population, comparator, effect sizes or how functional and biological age were measured. [1]
ARDD 2026: Boston debut and founding context
The description says ARDD is a conference dedicated to longevity biotechnology that brings together researchers, pharmaceutical executives, regulators, entrepreneurs and investors. It was founded by Alex Zhavoronkov in 2014. After years of growth in Europe, it made its North American debut in Boston at the David Rubenstein Treehouse at Harvard University on October 1–3, 2026. A ribbon-cutting ceremony led by Admiral Brian Christine, US Assistant Secretary for Health, opened the conference. [1]
Sponsors and organizers named in the ARDD 2026 description
The description states that ARDD 2026 was organized by Insilico Medicine with support from a long list of companies and organizations, including Eli Lilly, AstraZeneca, AbbVie, Novo Nordisk, Nestlé, XPRIZE Healthspan, Microsoft, BioAge and Retro Biosciences. It also invites readers to follow updates on ARDD 2027 in Boston. These are organizational details; the description gives no trial data, participant numbers or peer-reviewed results behind the rentosertib takeaway. [1]
Context & limits
This is a video description only; the video and transcript were not reviewed. The rentosertib takeaway is a conference summary without reported population, comparator, effect sizes, measurement methods or peer-reviewed results. It is not evidence of a human lifespan benefit.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
AI-discovered rentosertib showed Phase 2 functional and
supporting a “dual-purpose” route from disease approval
ARDD was founded by Alex Zhavoronkov in
About this video
Creator description · original textText language: English
ARDD · 29 min · Source published: 2026-10-19
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.